To evaluate the safety and efficacy of a treatment regimen combining epirubicin, ifosfamide, and nivolumab for advanced undifferentiated pleomorphic sarcoma.
Administered the combination of epirubicin, ifosfamide, and nivolumab as the first-line treatment.
Monitored patient safety and treatment outcomes.
Evaluated treatment feasibility in clinical practice.
The treatment was found to be safe and well-tolerated.
Demonstrated high activity against advanced undifferentiated pleomorphic sarcoma.
Supported its use as a viable first-line treatment option.
Abstract
The combination of epirubicin, ifosfamide, and nivolumab is a safe, feasible, and highly active treatment for advanced UPS.